SCHEMBL5082858

SCHEMBL5082858

COc1ccc(C(=N)c2ccc(OC)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 1/20 0.67
PRSS2 P07478 1/20 0.67
PRSS3 P35030 1/20 0.67
CES2 O00748 2/20 0.58
CES1 P23141 2/20 0.58
CA1 P00915 5/20 0.58
CA2 P00918 5/20 0.58
CA12 O43570 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58
ALDH1A1 P00352 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NR1I2 O75469 1/20 0.54
PARP1 P09874 1/20 0.54
PARP10 Q53GL7 1/20 0.54
PARP2 Q9UGN5 1/20 0.54
PARP4 Q9UKK3 1/20 0.54
PTGIR P43119 1/20 0.53
KDM4E B2RXH2 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4445973 0.91 CES2 (0.64) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL8066297 0.89 RAB9A (0.66) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL15372988 0.87 PRSS1 (0.53) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL18640413 0.85 ACHE (0.58) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL12175336 0.82 PRSS1 (0.64) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL16424951 0.81 CTSK (0.51) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL10994186 0.80 PRSS1 (0.61) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL10753412 0.80 PRSS1 (0.61) PRSS1PRSS2PRSS3CES2CES1
SCHEMBL428892 0.80 PRSS1 (1.00) PRSS1PRSS2PRSS3CA1CA2
SCHEMBL12669446 0.80 PRSS1 (0.61) PRSS1PRSS2PRSS3CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007055698-A1 IMPROVED METHOD FOR MAKING AMINO ACID CLYCOSIDES AND GLYCOPEPTIDES THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2007-05-18 WO claimed
EP-4365162-A2 A PROCESS FOR THE PREPARATION OF N-(BIS(4-METHOXYPHENYL)METHYL)-6-OXO-2-(PYRIDAZIN-3-YL)-1,6-DIHYDROPYRIMIDINE-5-CARBOXAMIDE Intervet International B.V. (NL) 2024-05-08 EP disclosed
US-20240088343-A1 ELECTRODE MANUFACTURING METHOD AND ELECTRODE MANUFACTURING APPARATUS RICOH COMPANY, LTD. (JP) 2024-03-14 US disclosed
US-20240051943-A1 A PROCESS FOR THE PREPARATION OF N-(BIS(4-METHOXYPHENYL)METHYL)-6-OXO-2-(PYRIDAZIN-3-YL)-1,6-DIHYDROPYRIMIDINE-5-CARBOXAMIDE INTERVET INC. (US) 2024-02-15 US disclosed
EP-4263528-A1 A PROCESS FOR THE PREPARATION OF N-(BIS(4-METHOXYPHENYL)METHYL)-6-OXO-2-(PYRIDAZIN-3-YL)-1,6-DIHYDROPYRIMIDINE-5-CARBOXAMIDE Intervet International B.V. (NL) 2023-10-25 EP disclosed
CN-116762180-A Electrode manufacturing method and electrode manufacturing apparatus 株式会社理光 2023-09-15 CN disclosed
CN-116222864-A Flexible capacitive three-dimensional force sensor constructed by taking composite material as dielectric layer and preparation method thereof 浙江理工大学 2023-06-06 CN disclosed
US-11545700-B2 Power storage system with integrally formed voltage detecting field effect transistor and manufacturing method thereof RICOH COMPANY, LTD. (JP) 2023-01-03 US disclosed
WO-2022136206-A1 A PROCESS FOR THE PREPARATION OF N-(BIS(4-METHOXYPHENYL)METHYL)-6-OXO-2-(PYRIDAZIN-3-YL)-1,6-DIHYDROPYRIMIDINE-5-CARBOXAMIDE INTERVET INTERNATIONAL B.V. (NL) 2022-06-30 WO disclosed
WO-2022136206-A1 A PROCESS FOR THE PREPARATION OF N-(BIS(4-METHOXYPHENYL)METHYL)-6-OXO-2-(PYRIDAZIN-3-YL)-1,6-DIHYDROPYRIMIDINE-5-CARBOXAMIDE INTERVET INTERNATIONAL B.V. (NL) 2022-06-30 WO disclosed
EP-2597095-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Takeda Pharmaceutical Company Limited (JP) 2013-05-29 EP disclosed
US-20130131050-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-23 US disclosed
EP-1592698-B1 PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF TAKASAGO PERFUMERY CO LTD (JP) 2008-03-26 EP disclosed
WO-2007055698-A1 IMPROVED METHOD FOR MAKING AMINO ACID CLYCOSIDES AND GLYCOPEPTIDES THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2007-05-18 WO disclosed
US-7129367-B2 Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-10-31 US disclosed
US-20060058542-A1 Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-03-16 US disclosed
EP-1167372-B1 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst TAKASAGO PERFUMERY CO LTD (JP) 2003-12-10 EP disclosed
US-6455720-B1 AS CATALYSTS TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-09-24 US disclosed
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-05-16 US disclosed
EP-1167372-A1 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst Takasago International Corporation (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst DDT, PDCD11, PLD2 PRSS1 4371/4885PRSS2 3084/4885PRSS3 3971/4885
US-20240051943-A1 A PROCESS FOR THE PREPARATION OF N-(BIS(4-METHOXYPHENYL)METHYL)-6-OXO-2-(PYRIDAZIN-3-YL)-1,6-DIHYDROPYRIMIDINE-5-CARBOXAMIDE DPYD, TPMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PRSS1 2849/4885PRSS2 2488/4885PRSS3 3845/4885
US-20060058542-A1 Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex SQLE, C9, PHOSPHO1 PRSS1 4256/4885PRSS2 4479/4885PRSS3 4071/4885
US-20130131050-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LTB4R2, LTB4R, LTC4S PRSS1 1852/4885PRSS2 2560/4885PRSS3 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.